{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T15:10:21Z","timestamp":1785769821398,"version":"3.56.0"},"reference-count":42,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"15","license":[{"start":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T00:00:00Z","timestamp":1775779200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,4,10]]},"abstract":"<jats:p>\n                    Serum biomarkers that reflect both tumor burden and host response may provide valuable prognostic information in metastatic colorectal cancer (mCRC). Carbohydrate antigen 19-9 (CA19-9) and albumin levels have been associated with disease outcomes; however, the prognostic value of their ratio has not been evaluated in de novo mCRC. This study aimed to investigate the prognostic significance of the pretreatment CA19-9\/albumin ratio in patients with de novo mCRC who were treated with standard combination chemotherapy and biologic agents. A total of 178 patients diagnosed with de novo mCRC between 2013 and 2024 were retrospectively analyzed. The CA19-9\/albumin ratio was calculated by dividing serum CA19-9 (U\/mL) by albumin (g\/dL), and the optimal cutoff value was determined using receiver operating characteristic curve analysis. Patients were classified into low- and high-ratio groups. Progression-free survival (PFS) and overall survival (OS) were estimated using the Kaplan\u2013Meier method, and independent prognostic factors were identified through multivariate Cox regression analyses. The optimal cutoff value for the CA19-9\/albumin ratio was 5.81. Patients with a high-ratio had significantly shorter PFS (median 9.6 vs 16.1 months,\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    \u2005=\u2005.002) and OS (median 23.3 vs 32.6 months,\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    \u2005=\u2005.005) compared with those with a low-ratio. In multivariate analyses, a high CA19-9\/albumin ratio independently predicted shorter PFS (hazard ratio 0.60, 95% confidence interval [CI] 0.41\u20130.89,\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    \u2005=\u2005.011) and OS (hazard ratio 0.66, 95% confidence interval 0.44\u20130.99,\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    \u2005=\u2005.042). The CA19-9\/albumin ratio is a simple, inexpensive, and easily obtainable serum biomarker that independently predicts survival in patients with de novo mCRC. This composite biomarker may better reflect the combined effects of tumor burden and host status, providing additional prognostic value beyond conventional markers. Prospective multicenter studies are warranted for further validation.\n                  <\/jats:p>","DOI":"10.1097\/md.0000000000048191","type":"journal-article","created":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T17:01:58Z","timestamp":1775840518000},"page":"e48191","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Prognostic value of the pretreatment CA19-9\/Albumin ratio in de novo metastatic colorectal cancer: A retrospective cohort study"],"prefix":"10.1097","volume":"105","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6116-3936","authenticated-orcid":false,"given":"Murat","family":"G\u00fcnaltili","sequence":"first","affiliation":[{"name":"Division of Medical Oncology, Department of Internal Medicine, Cerrahpa\u015fa Faculty of Medicine, Istanbul University-Cerrahpa\u015fa, Istanbul, Turkey."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Murad","family":"Guliyev","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, Department of Internal Medicine, Cerrahpa\u015fa Faculty of Medicine, Istanbul University-Cerrahpa\u015fa, Istanbul, Turkey."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zeliha","family":"Birsin","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, Department of Internal Medicine, Cerrahpa\u015fa Faculty of Medicine, Istanbul University-Cerrahpa\u015fa, Istanbul, Turkey."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emir","family":"\u00c7erme","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, Department of Internal Medicine, Cerrahpa\u015fa Faculty of Medicine, Istanbul University-Cerrahpa\u015fa, Istanbul, Turkey."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vali","family":"Aliyev","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, Department of Internal Medicine, Cerrahpa\u015fa Faculty of Medicine, Istanbul University-Cerrahpa\u015fa, Istanbul, Turkey."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hamza","family":"Abbasov","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, Department of Internal Medicine, Cerrahpa\u015fa Faculty of Medicine, Istanbul University-Cerrahpa\u015fa, Istanbul, Turkey."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Selin","family":"Cebeci","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, Department of Internal Medicine, Cerrahpa\u015fa Faculty of Medicine, Istanbul University-Cerrahpa\u015fa, Istanbul, Turkey."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ebru","family":"\u00c7i\u00e7ek","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, Department of Internal Medicine, Cerrahpa\u015fa Faculty of Medicine, Istanbul University-Cerrahpa\u015fa, Istanbul, Turkey."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehmet Cem","family":"Fidan","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, Department of Internal Medicine, Cerrahpa\u015fa Faculty of Medicine, Istanbul University-Cerrahpa\u015fa, Istanbul, Turkey."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nebi Serkan","family":"Demirci","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, Department of Internal Medicine, Cerrahpa\u015fa Faculty of Medicine, Istanbul University-Cerrahpa\u015fa, Istanbul, Turkey."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00d6zkan","family":"Alan","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, Department of Internal Medicine, Cerrahpa\u015fa Faculty of Medicine, Istanbul University-Cerrahpa\u015fa, Istanbul, Turkey."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20260410","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"R2-20260410","first-page":"233","article-title":"Colorectal cancer statistics, 2023.","volume":"73","author":"Siegel","year":"2023","journal-title":"CA Cancer J Clin"},{"key":"R3-20260410","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.annonc.2024.11.012","article-title":"Pembrolizumab versus chemotherapy in microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer: 5-year follow-up from the randomized phase III KEYNOTE-177 study.","volume":"36","author":"Andr\u00e9","year":"2025","journal-title":"Ann Oncol"},{"key":"R4-20260410","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/S0140-6736(24)02848-4","article-title":"Nivolumab plus ipilimumab versus nivolumab in microsatellite instability-high metastatic colorectal cancer (CheckMate 8HW): a randomised, open-label, phase 3 trial.","volume":"405","author":"Andr\u00e9","year":"2025","journal-title":"Lancet"},{"key":"R5-20260410","doi-asserted-by":"crossref","first-page":"5322","DOI":"10.1158\/1078-0432.CCR-14-0332","article-title":"Mismatch repair status and BRAF mutation status in metastatic colorectal cancer patients: a pooled analysis of the CAIRO, CAIRO2, COIN, and FOCUS studies.","volume":"20","author":"Venderbosch","year":"2014","journal-title":"Clin Cancer Res"},{"key":"R6-20260410","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1056\/NEJMoa0805019","article-title":"Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer.","volume":"360","author":"Van Cutsem","year":"2009","journal-title":"N Engl J Med"},{"key":"R7-20260410","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1056\/NEJMoa032691","article-title":"Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.","volume":"350","author":"Hurwitz","year":"2004","journal-title":"N Engl J Med"},{"key":"R8-20260410","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1093\/annonc\/mdp449","article-title":"The impact of carcinoembryonic antigen flare in patients with advanced colorectal cancer receiving first-line chemotherapy.","volume":"21","author":"Strimpakos","year":"2010","journal-title":"Ann Oncol"},{"key":"R9-20260410","doi-asserted-by":"crossref","first-page":"4289","DOI":"10.7314\/APJCP.2013.14.7.4289","article-title":"CEA and CA 19-9 are still valuable markers for the prognosis of colorectal and gastric cancer patients.","volume":"14","author":"Sisik","year":"2013","journal-title":"Asian Pac J Cancer Prev"},{"key":"R10-20260410","doi-asserted-by":"crossref","first-page":"1501436","DOI":"10.3389\/fsurg.2025.1501436","article-title":"Prognostic value of preoperative and postoperative serum CEA in colorectal signet ring cell carcinoma.","volume":"12","author":"Zheng","year":"2025","journal-title":"Front Surg"},{"key":"R11-20260410","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1007\/s13304-024-01774-x","article-title":"The prognostic value of combined preoperative PLR and CA19-9 in patients with resectable gallbladder cancer.","volume":"76","author":"Liu","year":"2024","journal-title":"Updates Surg"},{"key":"R12-20260410","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1186\/s12885-017-3738-y","article-title":"Diagnostic and prognostic value of CEA, CA19-9, AFP and CA125 for early gastric cancer.","volume":"17","author":"Feng","year":"2017","journal-title":"BMC Cancer"},{"key":"R13-20260410","first-page":"767","article-title":"Carcinoembryonic antigen and carbohydrate antigen 19-9 are prognostic predictors of colorectal cancer with unresectable liver metastasis.","volume":"3","author":"Mitsuyama","year":"2012","journal-title":"Oncol Lett"},{"key":"R14-20260410","first-page":"100907","article-title":"The prognostic role of circulating CA19-9 and CEA in patients with colorectal cancer.","volume":"43","author":"Gramkow","year":"2025","journal-title":"Cancer Treat Res Commun"},{"key":"R15-20260410","doi-asserted-by":"crossref","first-page":"3810","DOI":"10.7150\/jca.31375","article-title":"High pretreatment serum CA19-9 level predicts a poor prognosis for patients with stage III colon cancer after curative resection and adjuvant chemotherapy.","volume":"10","author":"Zhou","year":"2019","journal-title":"J Cancer"},{"key":"R16-20260410","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1007\/s00423-021-02236-3","article-title":"Optimal cutoff value of preoperative CEA and CA19-9 for prognostic significance in patients with stage II\/III colon cancer.","volume":"406","author":"Mizuno","year":"2021","journal-title":"Langenbecks Arch Surg"},{"key":"R17-20260410","doi-asserted-by":"crossref","first-page":"e493","DOI":"10.1016\/S1470-2045(14)70263-3","article-title":"Cancer-related inflammation and treatment effectiveness.","volume":"15","author":"Diakos","year":"2014","journal-title":"Lancet Oncol"},{"key":"R18-20260410","first-page":"223","article-title":"Systemic inflammation, nutritional status and survival in patients with cancer.","volume":"12","author":"McMillan","year":"2009","journal-title":"Curr Opin Clin Nutr Metab Care"},{"key":"R19-20260410","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.immuni.2019.06.025","article-title":"Inflammation and cancer: triggers, mechanisms, and consequences.","volume":"51","author":"Greten","year":"2019","journal-title":"Immunity"},{"key":"R20-20260410","doi-asserted-by":"crossref","first-page":"16717","DOI":"10.1038\/s41598-017-16955-5","article-title":"The role of the systemic inflammatory response in predicting outcomes in patients with operable cancer: systematic review and meta-analysis.","volume":"7","author":"Dolan","year":"2017","journal-title":"Sci Rep"},{"key":"R21-20260410","doi-asserted-by":"crossref","first-page":"667154","DOI":"10.3389\/fsurg.2021.667154","article-title":"Prognostic value of combined preoperative carcinoembryonic antigen and prognostic nutritional index in patients with stage II-III colon cancer.","volume":"8","author":"Xu","year":"2021","journal-title":"Front Surg"},{"key":"R22-20260410","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/s12957-025-03662-z","article-title":"Prognostic value and clinicopathological significance of pre-and post-treatment systemic immune-inflammation index in colorectal cancer patients: a meta-analysis.","volume":"23","author":"Tan","year":"2025","journal-title":"World J Surg Oncol"},{"key":"R23-20260410","doi-asserted-by":"crossref","first-page":"0038","DOI":"10.5152\/cjm.2025.25038","article-title":"Evaluating the prognostic role of pan-immune inflammation value in patients with advanced non-small cell lung cancer treated with nivolumab.","volume":"49","author":"Guliyev","year":"2025","journal-title":"Cerrahpa\u015fa Med J"},{"key":"R24-20260410","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1186\/1475-2891-9-69","article-title":"Pretreatment serum albumin as a predictor of cancer survival: a systematic review of the epidemiological literature.","volume":"9","author":"Gupta","year":"2010","journal-title":"Nutr J"},{"issue":"4 Suppl 2","key":"R25-20260410","doi-asserted-by":"crossref","first-page":"S143","DOI":"10.1097\/01.mcg.0000155514.17715.39","article-title":"Inhibition of albumin synthesis in chronic diseases: molecular mechanisms.","volume":"39","author":"Chojkier","year":"2005","journal-title":"J Clin Gastroenterol"},{"key":"R26-20260410","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1007\/s00384-010-1113-4","article-title":"Low preoperative serum albumin in colon cancer: a risk factor for poor outcome.","volume":"26","author":"Lai","year":"2011","journal-title":"Int J Colorectal Dis"},{"key":"R27-20260410","doi-asserted-by":"crossref","first-page":"1798","DOI":"10.1186\/s40064-016-3529-y","article-title":"The significance of the C-reactive protein to albumin ratio as a marker for predicting survival and monitoring chemotherapeutic effectiveness in patients with unresectable metastatic colorectal cancer.","volume":"5","author":"Shibutani","year":"2016","journal-title":"Springerplus"},{"key":"R28-20260410","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/s12885-021-09113-8","article-title":"Prognostic value of preoperative high-sensitivity modified Glasgow prognostic score in advanced colon cancer: a retrospective observational study.","volume":"22","author":"Kasahara","year":"2022","journal-title":"BMC Cancer"},{"key":"R29-20260410","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1186\/s40880-017-0260-1","article-title":"Prognostic value of preoperative prognostic nutritional index and its associations with systemic inflammatory response markers in patients with stage III colon cancer.","volume":"36","author":"Peng","year":"2017","journal-title":"Chin J Cancer"},{"key":"R30-20260410","doi-asserted-by":"crossref","first-page":"14","DOI":"10.37047\/jos.galenos.2025.2024.106668","article-title":"Prognostic significance of inflammatory and nutritional biomarkers in patients with metastatic gastric cancer.","volume":"11","author":"Guliyev","year":"2025","journal-title":"J Oncol Sci"},{"key":"R31-20260410","doi-asserted-by":"crossref","first-page":"e202400491","DOI":"10.1002\/cmdc.202400491","article-title":"Tumor-associated carbohydrate antigen 19-9 (CA 19-9), a promising target for antibody-based detection, diagnosis, and immunotherapy of cancer.","volume":"19","author":"Nakisa","year":"2024","journal-title":"ChemMedChem"},{"key":"R32-20260410","doi-asserted-by":"crossref","first-page":"21","DOI":"10.3390\/diseases9010021","article-title":"Diagnostic and prognostic value of CEA and CA19-9 in colorectal cancer.","volume":"9","author":"Lakemeyer","year":"2021","journal-title":"Diseases"},{"key":"R33-20260410","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1186\/s12885-022-10051-2","article-title":"Preoperative serum CA19-9 should be routinely measured in the colorectal patients with preoperative normal serum CEA: a multicenter retrospective cohort study.","volume":"22","author":"Li","year":"2022","journal-title":"BMC Cancer"},{"key":"R34-20260410","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1002\/jso.25209","article-title":"NARCA: a novel prognostic scoring system using neutrophil-albumin ratio and Ca19-9 to predict overall survival in palliative pancreatic cancer.","volume":"118","author":"Tingle","year":"2018","journal-title":"J Surg Oncol"},{"key":"R35-20260410","doi-asserted-by":"crossref","first-page":"4172","DOI":"10.7150\/jca.49242","article-title":"Prognostic value of the albumin-to-\u03b3-glutamyltransferase ratio for gallbladder cancer patients and establishing a nomogram for overall survival.","volume":"12","author":"Sun","year":"2021","journal-title":"J Cancer"},{"key":"R36-20260410","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1038\/s41598-020-80778-0","article-title":"Combining CRP and CA19-9 in a novel prognostic score in pancreatic ductal adenocarcinoma.","volume":"11","author":"Nurmi","year":"2021","journal-title":"Sci Rep"},{"key":"R37-20260410","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1002\/jso.20329","article-title":"Neutrophil-lymphocyte ratio as a prognostic factor in colorectal cancer.","volume":"91","author":"Walsh","year":"2005","journal-title":"J Surg Oncol"},{"key":"R38-20260410","first-page":"264","article-title":"Are markers of systemic inflammation good prognostic indicators in colorectal cancer?","volume":"16","author":"Rossi","year":"2017","journal-title":"Clin Colorectal Cancer"},{"key":"R39-20260410","doi-asserted-by":"crossref","first-page":"216","DOI":"10.3109\/1354750X.2012.656705","article-title":"Clinical significance of preoperative neutrophil-lymphocyte versus platelet-lymphocyte ratio in patients with operable colorectal cancer.","volume":"17","author":"Kwon","year":"2012","journal-title":"Biomarkers"},{"key":"R40-20260410","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s12029-021-00616-y","article-title":"Prognostic significance of neutrophil-lymphocyte ratio and platelet-lymphocyte ratio in metastatic colorectal cancer.","volume":"53","author":"Bulut","year":"2022","journal-title":"J Gastrointest Cancer"},{"key":"R41-20260410","first-page":"357","article-title":"Prognostic biomarkers in metastatic colorectal cancer: delta prognostic nutritional index, delta neutrophil to lymphocyte ratio, and delta platelet to lymphocyte ratio.","volume":"31","author":"Kocak","year":"2023","journal-title":"Support Care Cancer"},{"key":"R42-20260410","doi-asserted-by":"crossref","first-page":"100606","DOI":"10.1016\/j.esmoop.2022.100606","article-title":"Bone metastases are associated with worse prognosis in patients affected by metastatic colorectal cancer treated with doublet or triplet chemotherapy plus bevacizumab: a subanalysis of the TRIBE and TRIBE2 trials.","volume":"7","author":"Dell\u2019Aquila","year":"2022","journal-title":"ESMO Open"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/MD.0000000000048191","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T14:22:01Z","timestamp":1785766921000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/MD.0000000000048191"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,10]]},"references-count":42,"journal-issue":{"issue":"15","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000048191","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,10]]},"assertion":[{"value":"2025-11-21","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-03-13","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}